Company Overview and News

to your dashboard

Headline News

Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug

2018-01-14 seekingalpha
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US. The funds will underwrite Phase III development of its GKA product and commercialization. Ultimately, Hua hopes dorzagliatin will generate annual revenues of $3 billion, a 15% slice of the China type 2 diabetes market, once the drug is approved. (147-0)

Nektar Therapeutics: Continued Upside In 2018

2018-01-12 seekingalpha
For the 214 program, I look forward to results from the PROPEL and PIVOT trials along with an investigator sponsored study in sarcoma. (8-0)

Exelixis - Looking Good For 2018

2018-01-11 seekingalpha
Wider treatment options of this drug and continued growth should fuel product revenue growth, as the research pipeline looks strong as well. (39-0)

Bristol-Myers Squibb's (BMY) 36th Annual J.P. Morgan Healthcare Brokers Conference (Transcript)

2018-01-09 seekingalpha
Bristol-Myers Squibb Company (NYSE:BMY) 36th Annual J.P. Morgan Healthcare Conference January 9, 2018 1:00 PM ET (11-0)

After Irrational Fire Sale, It’s Time to Buy the Dip in Merck & Co., Inc. Stock

2018-01-09 investorplace
When it comes to pharmaceuticals, few names are as renowned as Merck & Co., Inc. (NYSE:MRK). Unfortunately in many cases, the bigger you are, the harder you fall. After a disappointing third quarter earnings report, Merck stock plummeted, leaving many question marks as to its trajectory in the new year. (107-0)

20 More Biopharma Catalysts Coming in 2018

2018-01-06 247wallst
Over the course of 2017, biopharmaceutical companies more or less kept pace with the markets, ending up with a return just a little higher than the S&P 500. But going in to 2018, these stocks have the potential to break out. Keep in mind there has been a rising tide from this nine-year raging bull market but plenty of factors have held biotechs back as well. (150-0)

EX-Dividend Schedule: Bristol-Myers Squibb Raised its Dividend by 2.6%; Will Trade Ex-Dividend on January 04, 2018

2018-01-03 accesswire
LONDON, UK / ACCESSWIRE / January 03, 2018 / Active-Investors has a free review on Bristol-Myers Squibb Co. (NYSE: BMY) ("Bristol-Myers") following the Company’s announcement that it will begin trading ex-dividend on January 04, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on January 03, 2018. (7-0)

Gilead Might Want To Consider Selling Its HCV Drug Business To China

2018-01-02 seekingalpha
Gilead shares have underperformed on concerns about declining hepatitis C, or HCV, product sales and fierce competition in the HIV drug business. (105-0)

Zach Hartman, PhD Positions For 2018: Oncology And Immunotherapy In Focus

2017-12-31 seekingalpha
Cell therapy is going to be a big factor in 2018, with companies like Gilead and Juno Therapeutics leading the charge. (50-0)

More and More Short Sellers Raising the Stakes in Major Pharma

2017-12-28 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside. (222-1)

Week In Review: Nearly $2 Billion Late-December Week For China Pharma Deals

2017-12-24 seekingalpha
Nanjing Legend Biotech received a $350 million upfront payment from Janssen Biotech, which will form a global partnership with Legend for its highly effective CAR-T candidate. In June, Legend, which was not previously well known, surprised the annual ASCO meeting with stunningly positive results from an early trial of the CAR-T molecule in patients with multiple myeloma. In addition to the $350 million initial payment, Janssen will make unspecified development and regulatory milestone payments to Legend. (455-3)

'Millennial Millions' - A DGI Portfolio Update

2017-12-21 seekingalpha
We started our daughter’s “Millennial Millions” DGI portfolio in 2015; it is now comprised of 38 positions. (349-0)

Grounds for concern over firms that snap up freeholds

He lives in a 16th-century moated manor house in Norfolk, with a 4,500 acre estate full of grey partridges and a penchant for collecting Old Masters. Earlier this year he was reported to have sold a prized collection of drawings by artists such as Michelangelo, Rubens and Goya to the Getty Museum for $100m. (76-0)

7 “Best of the Best” Mutual Funds to Buy

2017-12-15 investorplace
Arriving at a short list of the best mutual funds isn’t easy if you do it the right way, which is to begin with the entire universe of funds, use multiple screens to eliminate the worst, and then choose the best of what remains. (428-1)

Your Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing Agreement

2017-12-15 seekingalpha
Today we will discuss an article on Conatus Pharmaceuticals (CNAT) by Stephen Ayers, titled, “Conatus: Likely To Dash Ahead Of NASH Data.” (163-6)

CUSIP: 110122108